Connect with us

Headlines

FDA Approves Allergan’s Durysta Eye Implant for Glaucoma

The approval ‘marks a breakthrough milestone for the glaucoma community.’

mm

Published

on

DUBLIN — Allergan plc announced that the U.S. Food and Drug Administration has approved its New Drug Application for Durysta.

The drug is an eye implant designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It’s described as a 10 microgram biodegradable sustained-release bimatoprost implant.

“Today’s FDA approval marks a breakthrough milestone for the glaucoma community and provides a much-needed option for patients challenged with topical drops or needing alternative options,” said David Nicholson, chief research and development officer for Allergan. “At Allergan, our mission is to contribute meaningful strategies that help preserve people’s vision, while ensuring that therapies are mindful of the realities of administration and compliance. As a commitment to the ongoing development of this innovation, Allergan has five ongoing Phase 3 studies with DURYSTA to support further potential FDA label enhancement and rest of the world approvals.”

The drug “has the potential to significantly shift the paradigm for treating glaucoma,” said Dr. Felipe Medeiros, Distinguished Professor of Ophthalmology and vice-chair for technology, director clinical research unit, Department of Ophthalmology, Duke University.

With the launch of Durysta, Allergan expands availability of Allergan EyeCue, a reimbursement service for eyecare professionals to facilitate patient benefit verification, savings program enrollment for eligible patients, and prior authorization assistance for Allergan Eye Care products.

Advertisement

Advertisement

SPONSORED VIDEO

SPONSORED BY TOPCON HEALTHCARE

Perform Refraction from Anywhere with RDx

Now more than ever, you need to grow your practice beyond your physical location and deliver quality eye exams from virtually anywhere. Topcon RDx® is an innovative ocular telehealth platform that allows you to connect to your office remotely and conduct comprehensive eye exams, without sacrificing the quality care you provide.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular